PROTECT Study
Probiotics to Treat HSIL and Reduce Persistent High-Risk HPV Infection in Women and Men Living with HIV
Purpose of the Study
The study aims to:
- Evaluate the efficacy of EXE-346 in inducing regression of anal HSIL at Week 36 among people living with HIV.
- Evaluate the efficacy of EXE-346 in promoting clearance of HPV in anal swabs at Week 36 among people living with HIV.
- Determine whether changes in the microbiome associated with the use of EXE-346 correlate with anal HSIL regression or HPV clearance at Week 36.
Protocol Summary
This study is focused on the treatment of anal high-grade squamous intraepithelial lesions (HSIL) in people with HIV, with the ultimate goal of applying this approach toward the prevention of anal cancer in this population.
Basic Eligibility Criteria
Adults living with HIV who are on stable antiretroviral therapy (ART), have recently been diagnosed with anal high-grade squamous intraepithelial lesions (HSIL), are willing to take a twice-daily probiotic or placebo, and are willing to use a highly effective method of contraception. Participants must have no history of anal or cervical cancer and must not currently be receiving chemotherapy or immunosuppressive therapy.
Study Site
UCSF Anal Neoplasia Clinic, Research and Education Center (ANCRE)
1600 Divisadero St., Third Floor
San Francisco, CA 94115
For More Information
Jenn Marino, CCRC
[email protected]
William Juarez
[email protected]
ARCH Study
Burden and Correlates of Anal High-Grade Squamous Intraepithelial Lesions (HSIL) Among Renal Transplant Recipients (RTRs)
Purpose of the Study
The study aims to:
- Determine the prevalence of anal high-grade squamous intraepithelial lesions (HSIL) in people who are 10 or more years post-renal transplant.
- Determine the prevalence of anal high-risk HPV infection in people who are 10 or more years post-renal transplant.
- Identify risk factors associated with these diagnoses among renal transplant recipients.
Protocol Summary
Single-visit study looking at the rate of HPV infection and anal lesions in renal transplant recipients.
Basic Eligibility Criteria
Adults whose first renal transplant was more than 10 years ago, including people who have received one or more kidney transplants, with no history of anal cancer, HIV, or other organ transplants.
Study Site
UCSF Anal Neoplasia Clinic, Research and Education Center (ANCRE)
1600 Divisadero St., Third Floor
San Francisco, CA 94115
For More Information
Jenn Marino, CCRC
[email protected]
William Juarez
[email protected]